

# LACK OF EFFICACY OF DUPILUMAB IN THE TREATMENT OF KELOID DISORDER

Michael H Tirgan, MD, Jouni Uitto, MD, PhD

**Michael H Tirgan, MD<sup>1</sup>,  
Jouni Uitto, MD, PhD<sup>2</sup>**

<sup>1</sup>Keloid Research Foundation, New York, NY USA

<sup>2</sup>Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, and Joan and Joel Rosenbloom Center for Fibrotic Diseases, Thomas Jefferson University, Philadelphia, PA USA

## **Running Title**

Lack of Efficacy of Dupilumab in the Treatment of Keloid Disorder

**Word Count** - 186 Words

## **BACKGROUND**

Although localized treatments may be proper for patients with early and limited stage Keloid Disorder (KD), patients with more advanced stages of KD are in need of systemic treatments.

## **OBJECTIVE**

To assess potential clinical benefit from dupilumab in the treatment of patients with advanced stage keloid disorder.

## **MATERIAL AND METHODS**

This is a retrospective analysis of eight KD patients who received off-label treatment with dupilumab. Patients were followed according to standard clinical practice methods.

## **RESULTS**

Eight patients were treated with dupilumab for a minimum of two months (2 patients) up to twelve months (3 patients). Among eight treated patients, only one patient reported minimal response and was willing to continue the treatment beyond twelve months. One patient who was receiving dupilumab for the treatment of nasal polyps continued dupilumab despite progression of his keloids. Seven patients saw absolutely no benefit from dupilumab and were not willing to continue with the treatment. Three patients experienced clinical disease progression while on treatment with dupilumab.

## **CONCLUSIONS AND RELEVANCE**

Dupilumab lacks efficacy in the treatment of KD and should not be utilized outside the settings of well-designed clinical trials.